Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

Camila Peña; Eloisa Riva; Natalia Schutz; Luz Tarín-Arzaga; Humberto Martínez-Cordero; Virginia Bove; Rocío Osorio; Mauricio Chandía; Cecilia Beltrán; Javier Schulz; Daniela Cardemil; Carolina Contreras; Carmen Gloria Vergara; Javiera Donoso; Marcela Espinoza; Gabriel La Rocca; Hernán López-Vidal; Pilar León; Christine Rojas Hopkins; Pablo Soto; Sandra Aranda; Vivianne Torres; Macarena Roa; Paola Ochoa; Patricio Jose Duarte; Guillermina Remaggi; Sebastián Yantorno; Ariel Corzo; Soledad Zabaljauregui; Claudia Shanley; Sergio Lopresti; Sergio Orlando; Verónica Verri; Luis Quiroga; Carlos García; Vanesa Fernández; Jhoanna Ramirez; Alicia Molina; María Pacheco; Alex Mite; Inés Reyes; Brenner Sabando; Francisca Ramírez; Claudia Sossa; Virginia Abello; Henry Idrobo; Kenny Mauricio Galvez Cardenas; Domingo Saavedra; Guillermo Quintero; Raimundo Gazitúa; Lina Gaviria; Rigoberto Gomez; Mónica Osuna; Alicia Henao-Uribe; Omar Cantú-Martínez; David Gómez-Almaguer; Yarely Itzayana García-Navarrete; Antonio Cruz-Mora; Yahveth Cantero-Fortiz; Guillermo J. Ruiz-Argüelles; Dorotea Fantl

doi:10.1080/10428194.2020.1804558

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

Camila Peña, Eloisa Riva, Natalia Schutz, Luz Tarín-Arzaga, Humberto Martínez-Cordero, Virginia Bove, Rocío Osorio, Mauricio Chandía, Cecilia Beltrán, Javier Schulz, Daniela Cardemil, Carolina Contreras, Carmen Gloria Vergara, Javiera Donoso, Marcela Espinoza, Gabriel La Rocca, Hernán López-Vidal, Pilar León, Christine Rojas Hopkins, Pablo SotoSandra Aranda, Vivianne Torres, Macarena Roa, Paola Ochoa, Patricio Jose Duarte, Guillermina Remaggi, Sebastián Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Quiroga, Carlos García, Vanesa Fernández, Jhoanna Ramirez, Alicia Molina, María Pacheco, Alex Mite, Inés Reyes, Brenner Sabando, Francisca Ramírez, Claudia Sossa, Virginia Abello, Henry Idrobo, Kenny Mauricio Galvez Cardenas, Domingo Saavedra, Guillermo Quintero, Raimundo Gazitúa, Lina Gaviria, Rigoberto Gomez, Mónica Osuna, Alicia Henao-Uribe, Omar Cantú-Martínez, David Gómez-Almaguer, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Yahveth Cantero-Fortiz, Guillermo J. Ruiz-Argüelles, Dorotea Fantl

Research output: Articles / Notes › Scientific Article › peer-review

10 Scopus citations

Abstract

The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.

Original language	English
Pages (from-to)	3112-3119
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	61
Issue number	13
DOIs	https://doi.org/10.1080/10428194.2020.1804558
State	Published - 2020
Externally published	Yes

Keywords

Latin America
Multiple myeloma
autologous stem cell transplantation
proteasome inhibitor

Access to Document

10.1080/10428194.2020.1804558

Cite this

Peña, C., Riva, E., Schutz, N., Tarín-Arzaga, L., Martínez-Cordero, H., Bove, V., Osorio, R., Chandía, M., Beltrán, C., Schulz, J., Cardemil, D., Contreras, C., Vergara, C. G., Donoso, J., Espinoza, M., La Rocca, G., López-Vidal, H., León, P., Rojas Hopkins, C., ... Fantl, D. (2020). Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leukemia and Lymphoma, 61(13), 3112-3119. https://doi.org/10.1080/10428194.2020.1804558

@article{1d306c89f27f407e8b731030cb6d2083,

title = "Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study",

abstract = "The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.",

keywords = "Latin America, Multiple myeloma, autologous stem cell transplantation, proteasome inhibitor",

author = "Camila Pe{\~n}a and Eloisa Riva and Natalia Schutz and Luz Tar{\'i}n-Arzaga and Humberto Mart{\'i}nez-Cordero and Virginia Bove and Roc{\'i}o Osorio and Mauricio Chand{\'i}a and Cecilia Beltr{\'a}n and Javier Schulz and Daniela Cardemil and Carolina Contreras and Vergara, {Carmen Gloria} and Javiera Donoso and Marcela Espinoza and {La Rocca}, Gabriel and Hern{\'a}n L{\'o}pez-Vidal and Pilar Le{\'o}n and {Rojas Hopkins}, Christine and Pablo Soto and Sandra Aranda and Vivianne Torres and Macarena Roa and Paola Ochoa and Duarte, {Patricio Jose} and Guillermina Remaggi and Sebasti{\'a}n Yantorno and Ariel Corzo and Soledad Zabaljauregui and Claudia Shanley and Sergio Lopresti and Sergio Orlando and Ver{\'o}nica Verri and Luis Quiroga and Carlos Garc{\'i}a and Vanesa Fern{\'a}ndez and Jhoanna Ramirez and Alicia Molina and Mar{\'i}a Pacheco and Alex Mite and In{\'e}s Reyes and Brenner Sabando and Francisca Ram{\'i}rez and Claudia Sossa and Virginia Abello and Henry Idrobo and {Galvez Cardenas}, {Kenny Mauricio} and Domingo Saavedra and Guillermo Quintero and Raimundo Gazit{\'u}a and Lina Gaviria and Rigoberto Gomez and M{\'o}nica Osuna and Alicia Henao-Uribe and Omar Cant{\'u}-Mart{\'i}nez and David G{\'o}mez-Almaguer and Garc{\'i}a-Navarrete, {Yarely Itzayana} and Antonio Cruz-Mora and Yahveth Cantero-Fortiz and Ruiz-Arg{\"u}elles, {Guillermo J.} and Dorotea Fantl",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

doi = "10.1080/10428194.2020.1804558",

language = "Ingl{\'e}s",

volume = "61",

pages = "3112--3119",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "13",

}

Peña, C, Riva, E, Schutz, N, Tarín-Arzaga, L, Martínez-Cordero, H, Bove, V, Osorio, R, Chandía, M, Beltrán, C, Schulz, J, Cardemil, D, Contreras, C, Vergara, CG, Donoso, J, Espinoza, M, La Rocca, G, López-Vidal, H, León, P, Rojas Hopkins, C, Soto, P, Aranda, S, Torres, V, Roa, M, Ochoa, P, Duarte, PJ, Remaggi, G, Yantorno, S, Corzo, A, Zabaljauregui, S, Shanley, C, Lopresti, S, Orlando, S, Verri, V, Quiroga, L, García, C, Fernández, V, Ramirez, J, Molina, A, Pacheco, M, Mite, A, Reyes, I, Sabando, B, Ramírez, F, Sossa, C, Abello, V, Idrobo, H, Galvez Cardenas, KM, Saavedra, D, Quintero, G, Gazitúa, R, Gaviria, L, Gomez, R, Osuna, M, Henao-Uribe, A, Cantú-Martínez, O, Gómez-Almaguer, D, García-Navarrete, YI, Cruz-Mora, A, Cantero-Fortiz, Y, Ruiz-Argüelles, GJ & Fantl, D 2020, 'Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study', Leukemia and Lymphoma, vol. 61, no. 13, pp. 3112-3119. https://doi.org/10.1080/10428194.2020.1804558

TY - JOUR

T1 - Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management

T2 - a GELAMM study

AU - Peña, Camila

AU - Riva, Eloisa

AU - Schutz, Natalia

AU - Tarín-Arzaga, Luz

AU - Martínez-Cordero, Humberto

AU - Bove, Virginia

AU - Osorio, Rocío

AU - Chandía, Mauricio

AU - Beltrán, Cecilia

AU - Schulz, Javier

AU - Cardemil, Daniela

AU - Contreras, Carolina

AU - Vergara, Carmen Gloria

AU - Donoso, Javiera

AU - Espinoza, Marcela

AU - La Rocca, Gabriel

AU - López-Vidal, Hernán

AU - León, Pilar

AU - Rojas Hopkins, Christine

AU - Soto, Pablo

AU - Aranda, Sandra

AU - Torres, Vivianne

AU - Roa, Macarena

AU - Ochoa, Paola

AU - Duarte, Patricio Jose

AU - Remaggi, Guillermina

AU - Yantorno, Sebastián

AU - Corzo, Ariel

AU - Zabaljauregui, Soledad

AU - Shanley, Claudia

AU - Lopresti, Sergio

AU - Orlando, Sergio

AU - Verri, Verónica

AU - Quiroga, Luis

AU - García, Carlos

AU - Fernández, Vanesa

AU - Ramirez, Jhoanna

AU - Molina, Alicia

AU - Pacheco, María

AU - Mite, Alex

AU - Reyes, Inés

AU - Sabando, Brenner

AU - Ramírez, Francisca

AU - Sossa, Claudia

AU - Abello, Virginia

AU - Idrobo, Henry

AU - Galvez Cardenas, Kenny Mauricio

AU - Saavedra, Domingo

AU - Quintero, Guillermo

AU - Gazitúa, Raimundo

AU - Gaviria, Lina

AU - Gomez, Rigoberto

AU - Osuna, Mónica

AU - Henao-Uribe, Alicia

AU - Cantú-Martínez, Omar

AU - Gómez-Almaguer, David

AU - García-Navarrete, Yarely Itzayana

AU - Cruz-Mora, Antonio

AU - Cantero-Fortiz, Yahveth

AU - Ruiz-Argüelles, Guillermo J.

AU - Fantl, Dorotea

PY - 2020

Y1 - 2020

N2 - The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.

AB - The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.

KW - Latin America

KW - Multiple myeloma

KW - autologous stem cell transplantation

KW - proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85089856783&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1804558

DO - 10.1080/10428194.2020.1804558

M3 - Artículo Científico

C2 - 32844699

AN - SCOPUS:85089856783

SN - 1042-8194

VL - 61

SP - 3112

EP - 3119

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 13

ER -

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this